Paris, France – iPSirius today announced its decision to focus on advanced non-small cell lung cancer as the first indication for its comprehensive stem cell-based immunotherapy in the inaugural first-in-human clinical trial. Furthermore, the company declared its intention to apply for a clinical trial  licence and undertake the clinical trial in the United Kingdom, to leverage the integrated clinical infrastructure, there, as well as take advantage of the country’s extensive biotech expertise and the UK government’s commitment to innovative healthcare solutions. [Read more…]
Aspen Neuroscience Secures an for IND for ANPD001, a Novel Cell Therapy for Parkinson’s Disease
Aspen Neuroscience, a pioneering force in regenerative medicine, has received clearance from the U.S. FDA for its Investigational New Drug (IND) application for ANPD001. ANPD001 is a novel autologous (“self-derived”) cell therapy that has the potential to treat Parkinson’s Disease by replenishing lost dopamine neurons. This green light from the FDA propels Aspen Neuroscience into historic territory, initiating a clinical trial for ANPD001 in human patients. [Read more…]
Stem Cell Market Intelligence – “Make Smarter Decisions, Faster”
Stem cell market intelligence is defined as data relevant to the stem cell industry, gathered for the purpose of making informed business decisions. Business activities that market intelligence may support include:
- New product development
- Sales strategy
- Market strategy
- New client acquisition
Axol Bioscience and StrataStem to Deliver iPSC-Derived ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
Together, an extensive panel of consented patient samples and iPSC technology will advance AD drug development and patient stratification.
CAMBRIDGE, England & EDINBURGH, Scotland — Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples. Harnessing its stem cell expertise, Axol will reprogram these patient samples into induced Pluripotent Stem Cells (iPSCs) that can then be differentiated into a wide range of brain cells, including neurons and neuroinflammatory cells. Grown in vitro, these cells can provide patient specific human brain models from a large cohort of AD patients – to create a ‘clinical trial in a dish’. [Read more…]
StemBioSys Launches CELLvo™, Human iPSC-Derived Atrial Cardiomyocytes for Cardiotoxicity Screening
Developed in collaboration with REPROCELL, CELLvo™Â Atrial Cardiomyocyte delivers non-genetically modified human heart cells that are chamber specific and derived from iPS (stem) cells
SAN ANTONIO, June 13, 2023 — StemBioSys, Inc. (StemBioSys) announced the launch of CELLvo™Â Atrial Cardiomyocyte, a “chamber specific” human induced pluripotent stem cell derived cardiomyocyte (hiPSC-CM) designed to function identically to human atrial cardiomyocytes. StemBioSys developed CELLvo™Â Atrial Cardiomyocyte to empower pharmaceutical companies and academics with a more precise, efficient and cost-effective platform for screening new drug products in vitro for cardiotoxicity compared to animal models and other in-vitro methods currently in use. [Read more…]
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 79
- Next Page »